EverSea Medicines to acquire Hasten Biopharmaceuticals
Everest Medicines’ wholly owned subsidiary EverSea Medicines (Singapore) has signed a share purchase agreement to conditionally acquire Hasten Biopharmaceuticals, a…
09 Apr 2026
FDA seeks permanent future for rare pediatric priority review vouchers
The US Food and Drug Administration (FDA) is seeking to permanently authorise the rare pediatric disease priority review voucher (PRV) programme, putting an end to cycles of expirations and renewals…
09 Apr 2026
Shionogi secures $482m BARDA contract to tackle AMR crisis
Japanese pharma company Shionogi has secured a contract worth up to $482m with the US’s Biomedical Advanced Research and Development Authority (BARDA), as the American government looks to boost the…
09 Apr 2026
Jeito Capital secures over $1.2bn for new biopharma investments
Global independent private equity fund Jeito Capital has closed its second fund, Jeito II, surpassing its target of €1bn ($1.2bn), thereby establishing a significant new milestone for investment in European…
08 Apr 2026
Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic
Sidewinder Therapeutics has secured $137m in a Series B financing round to progress its pipeline of bispecific antibody-drug conjugates (ADCs) – marking the continued growth in investor interest over the…
08 Apr 2026
RoosterBio and MineBio team up to expand MSC solutions access in China
RoosterBio has entered an exclusive distributor partnership with MineBio Life Sciences to expand access to scalable, research-grade and current good manufacturing practice (cGMP)-grade mesenchymal stem cell (MSC) and exosome bioprocessing…
08 Apr 2026
Pharma industry laments Trump’s tariff on branded drugs
The pharmaceutical industry has widely criticised the US administration’s decision to impose a 100% tariff on branded drugs imported into the country, as trade bodies and analysts begin to dissect…